Study of urinary steroid hormone disorders: Difference between hepatocellular carcinoma in early stage and cirrhosis

Analytical and Bioanalytical Chemistry

Volumn 406, Issue 18, 2014, Pages 4325-4335

  Dai, Weidong ^a   Yin, Peiyuan ^a   Chen, Ping ^b   Kong, Hongwei ^a   Luo, Ping ^a   Xu, Zhiliang ^a   Lu, Xin ^a   Xu, Guowang ^a  

^a DALIAN INSTITUTE OF CHEMICAL PHYSICS   (China)

^b Zhejiang Chinese Medicine University   (China)

Author keywords

Biomarker; Hepatocellular carcinoma; LC MS; Liver cirrhosis; Metabolomics; Steroid hormone

Indexed keywords

BIOMARKERS; INDUCTIVELY COUPLED PLASMA; ISOTOPES; REGRESSION ANALYSIS;

HEPATOCELLULAR CARCINOMA; LC-MS; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; LIVER CIRRHOSIS; LOGISTIC REGRESSION ANALYSIS; METABOLOMICS; MULTIVARIATE STATISTICAL ANALYSIS; RECEIVER OPERATING CHARACTERISTIC ANALYSIS;

STEROID HORMONES;

ALLOTETRAHYDROCORTISOL; ALPHA FETOPROTEIN; BIOLOGICAL MARKER; CORTICOSTEROID; EPITESTOSTERONE; SEX HORMONE; TETRAHYDROCORTISOL;

ADULT; ANALOGS AND DERIVATIVES; AREA UNDER THE CURVE; CARCINOMA, HEPATOCELLULAR; CASE CONTROL STUDY; HUMAN; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; METABOLOMICS; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; PROCEDURES; STATISTICAL MODEL; URINE;

ADRENAL CORTEX HORMONES; ADULT; ALPHA-FETOPROTEINS; AREA UNDER CURVE; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; EPITESTOSTERONE; GONADAL STEROID HORMONES; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; LOGISTIC MODELS; MALE; METABOLOMICS; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; TETRAHYDROCORTISOL;

EID: 84903757828     PISSN: 16182642     EISSN: 16182650     Source Type: Journal    
DOI: 10.1007/s00216-014-7843-3     Document Type: Article

References (30)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127(12):2893-2917
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2):69-90
3. Ye G, Zhu B, Yao Z, Yin P, Lu X, Kong H, Fan F, Jiao B, Xu G (2012) Analysis of urinary metabolic signatures of early hepatocellular carcinoma recurrence after surgical removal using gas chromatography-mass spectrometry. J Proteome Res 11(8):4361-4372
4. Wu H, Xue R, Dong L, Liu T, Deng C, Zeng H, Shen X (2009) Metabolomic profiling of human urine in hepatocellular carcinoma patients using gas chromatography/mass spectrometry. Anal Chim Acta 648(1):98-104
5. Patterson AD, Maurhofer O, Beyoglu D, Lanz C, Krausz KW, Pabst T, Gonzalez FJ, Dufour JF, Idle JR (2011) Aberrant lipid metabolism in hepatocellular carcinoma revealed by plasma metabolomics and lipid profiling. Cancer Res 71(21):6590-6600
6. Zhou L, Wang Q, Yin P, Xing W, Wu Z, Chen S, Lu X, Zhang Y, Lin X, Xu G (2012) Serum metabolomics reveals the deregulation of fatty acids metabolism in hepatocellular carcinoma and chronic liver diseases. Anal Bioanal Chem 403(1):203-213
7. Tan Y, Yin P, Tang L, Xing W, Huang Q, Cao D, Zhao X, Wang W, Lu X, Xu Z (2012) Metabolomics study of stepwise hepatocarcinogenesis from the model rats to patients: potential biomarkers effective for small hepatocellular carcinoma diagnosis. Mol Cell Proteomics 11(2):M111.010694
8. Ressom HW, Xiao JF, Tuli L, Varghese RS, Zhou B, Tsai T-H, Nezami Ranjbar MR, Zhao Y, Wang J, Di Poto C, Cheema AK, Tadesse MG, Goldman R, Shetty K (2012) Utilization of metabolomics to identify serum biomarkers for hepatocellular carcinoma in patients with liver cirrhosis. Anal Chim Acta 743:90-100
9. Yin P, Wan D, Zhao C, Chen J, Zhao X, Wang W, Lu X, Yang S, Gu J, Xu G (2009) A metabonomic study of hepatitis B-induced liver cirrhosis and hepatocellular carcinoma by using RP-LC and HILIC coupled with mass spectrometry. Mol BioSyst 5(8):868-876
10. Chen T, Xie G, Wang X, Fan J, Qiu Y, Zheng X, Qi X, Cao Y, Su M, Wang X, Xu LX, Yen Y, Liu P, Jia W (2011) Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma. Mol Cell Proteomics 10(7)
11. Gann PH, Hennekens CH, Ma J, Longcope C, Stampfer MJ (1996) Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 88(16):1118-1126
12. Blair IA (2010) Analysis of estrogens in serum and plasma from postmenopausal women: past present, and future. Steroids 75(4-5):297-306
13. Claus EB, Schildkraut JM, Thompson WD, Risch NJ (1998) The genetic attributable risk of breast and ovarian cancer. Cancer 77(11):2318-2324
14. Lukanova A, Lundin E, Micheli A, Arslan A, Ferrari P, Rinaldi S, Krogh V, Lenner P, Shore RE, Biessy C, Muti P, Riboli E, Koenig KL, Levitz M, Stattin P, Berrino F, Hallmans G, Kaaks R, Toniolo P, Zeleniuch-Jacquotte A (2004) Circulating levels of sex steroid hormones and risk of endometrial cancer in postmenopausal women. Int J Cancer 108(3):425-432
15. Maria ND, Manno M, Villa E (2002) Sex hormones and liver cancer. Mol Cell Endocrinol 193(1):59-63
16. Yu MW, Cheng SW, Lin MW, Yang SY, Liaw YF, Chang HC, Hsiao TJ, Lin SM, Lee SD, Chen PJ (2000) Androgen-receptor gene CAG repeats, plasma testosterone levels, and risk of hepatitis B-related hepatocellular carcinoma. J Natl Cancer Inst 92(24):2023-2028
17. Chao Y, Chan WK, Huang YS, Teng HC, Wang SS, Lui WY, WhangPeng J, Lee SD (1996) Phase II study of flutamide in the treatment of hepatocellular carcinoma. Cancer 77(4):635-639
18. Grimaldi C, Bleiberg H, Gay F, Messner M, Rougier P, Kok TC, Cirera L, Cervantes A, De Greve J, Paillot B, Buset M, Nitti D, Sahmoud T, Duez N, Wils J (1998) Evaluation of antiandrogen therapy in unresectable hepatocellular carcinoma: results of a European organization for research and treatment of cancer multicentric double-blind trial. J Clin Oncol 16(2):411-417
19. Simonetti R, Liberati A, Angiolini C, Pagliaro L (1997) Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials. Ann Oncol 8(2):117-136
20. Gallo C, Daniele B, Gaeta G, Perrone F, Pignata S, D'Alfonso G, Signoriello G, Cremona F, Izzo F, Parisi V (1998) Tamoxifen in treatment of hepatocellular carcinoma: a randomised controlled trial. Lancet 352(9121):17-20
21. Liu C-L, Fan S-T, Ng IO-L, Lo C-M, Poon RT-P, Wong J (2000) Treatment of advanced hepatocellular carcinoma with tamoxifen and the correlation with expression of hormone receptors: a prospective randomized study. Am J Gastroenterol 95(1):218-222
22. Dai W, Huang Q, Yin P, Li J, Zhou J, Kong H, Zhao C, Lu X, Xu G (2012) Comprehensive and highly sensitive urinary steroid hormone profiling method based on stable isotope-labeling liquid chromatography-mass spectrometry. Anal Chem 84(23):10245-10251
23. Xu X, Veenstra TD, Fox SD, Roman JM, Issaq HJ, Falk R, Saavedra JE, Keefer LK, Ziegler RG (2005) Measuring fifteen endogenous estrogens simultaneously in human urine by high-performance liquid chromatography-mass spectrometry. Anal Chem 77(20):6646-6654
24. You L (2004) Steroid hormone biotransformation and xenobiotic induction of hepatic steroid metabolizing enzymes. Chem Biol Interact 147(3):233-246
25. Tanaka K, Sakai H, Hashizume M, Hirohata T (2000) Serum testosterone: estradiol ratio and the development of hepatocellular carcinoma among male cirrhotic patients. Cancer Res 60(18):5106-5110
26. Wang B, Chen D, Chen Y, Hu Z, Cao M, Xie Q, Chen Y, Xu J, Zheng S, Li L (2012) Metabonomic profiles discriminate hepatocellular carcinoma from liver cirrhosis by ultraperformance liquid chromatography-mass spectrometry. J Proteome Res 11(2):1217-1227
27. Zhou J, Yu L, Gao X, Hu J, Wang JP, Dai Z, Wang JF, Zhang ZY, Lu SH, Huang XW, Wang Z, Qiu SJ, Wang XY, Yang GH, Sun HC, Tang ZY, Wu Y, Zhu HG, Fan J (2011) Plasma MicroRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J Clin Oncol 29(36):4781-4788
28. Auprich M, Haese A, Walz J, Pummer K, de la Taille A, Graefen M, de Reijke T, Fisch M, Kil P, Gontero P (2010) External validation of urinary PCA3-based nomograms to individually predict prostate biopsy outcome. Eur Urol 58(5):727-732
29. Onodera H, Ukai K, Minami Y (1995) Hepatocellular carcinoma cases with five-year survival and prognostic factors affecting the survival time. Tohoku J Exp Med 176(4):203-211
30. Chen L, Ho DWY, Lee NPY, Sun S, Lam B, Wong KF, Yi X, Lau GK, Ng EWY, Poon TCW (2010) Enhanced detection of early hepatocellular carcinoma by serum SELDI-TOF proteomic signature combined with alpha-fetoprotein marker. Ann Surg Oncol 17(9):2518-2525